QNTM Quantum Biopharma Ltd.
Price Chart
Executive Summary
Quantum BioPharma disclosed that the FDA placed its lead drug candidate Lucid-MS (for multiple sclerosis) on clinical hold on May 28, 2026, pending additional information. The company is withdrawing previously disclosed timelines for Phase 2 trial initiation and interim data. Additionally, director Dr. Lakshmi P. Kotra resigned effective June 1, 2026. This is a material negative regulatory setback for the company's primary pipeline asset.
Actionable Insight
The clinical hold is a binary event for QNTM given the $34M market cap and Lucid-MS as the lead asset. Watch for the company's response package submission and FDA feedback; the hold duration is unpredictable. The director resignation adds governance uncertainty. Consider the stock at risk of significant downside until the hold is resolved.
Key Facts
- FDA placed IND for Lucid-MS (Lucid-21-302) on clinical hold on May 28, 2026
- Company withdrawing previously disclosed timelines for Phase 2 trial initiation and interim data milestones
- Director Dr. Lakshmi P. Kotra resigned from all positions effective June 1, 2026
- Company believes issues are addressable and plans to submit a response package
- Market cap is $34M — clinical hold on lead asset represents a major binary risk event
Financial Impact
No financial figures reported; clinical hold on lead drug candidate Lucid-MS places the company's primary value driver at risk and delays any potential revenue timeline indefinitely
Risk Factors
- Clinical hold may remain in place for a prolonged period or may not be lifted
- Additional studies or data may be required beyond current scope, increasing cash burn
- Director resignation signals potential internal challenges
- Withdrawn timelines create a valuation vacuum — no near-term catalysts
- Pre-revenue biotech with no approved products; dependent on financing for operations
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-002283 |
| Document: qntm6k060226.htm | 0001185185-26-002283 |
| Document: 0001185185-26-002283-index-headers.html | 0001185185-26-002283 |
| Document: 0001185185-26-002283-index.html | 0001185185-26-002283 |
| Document: 0001185185-26-002283.txt | 0001185185-26-002283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
4d ago
|
6-K
| $5.11 $4.88 | ▲ +4.50% | ▲ +3.81% | $4.26 (+16.63%) |
|
Jun 2, 2026
4d ago
|
6-K
| — | awaiting T+1 | — | — |
|
May 18, 2026
19d ago
|
6-K
| — | awaiting T+1 | — | — |
|
Apr 22, 2026
6w ago
|
6-K
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $4.26 (+27.16%) |
|
Apr 22, 2026
6w ago
|
Press Release
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $4.26 (+27.16%) |
|
Apr 2, 2026
9w ago
|
6-K
| $3.98 $3.58 | ▼ −10.05% | ▼ −10.53% | $4.26 (+7.04%) |
|
Apr 1, 2026
9w ago
|
6-K
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $4.26 (−3.40%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $4.26 (−3.40%) |
|
Mar 30, 2026
9w ago
|
Court Ruling
| $4.28 $4.83 | ▲ +12.85% | ▲ +9.96% | $4.26 (−0.47%) |
|
Mar 27, 2026
10w ago
|
6-K
| $4.77 $4.28 | ▼ −10.27% | ▼ −9.91% | $4.26 (−10.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access